A Phase 3 interventional study of Esomeprazole Na and Cimetidine in Bleeding Peptic Ulcer, sponsored by AstraZeneca. Completed at 12 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-03-08.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Peptic Ulcer Hemorrhage with a site in China — 1 open to participants now, 1 under way, none of them phase 3. Peptic Ulcer Hemorrhage · China.
Among the 12 studies in Peptic Ulcer Hemorrhage with a site in China, this one is the only one that started in 2013, is one of 3 in phase 3, and was the 10th registered.
55 studies on the registry are indexed under Peptic Ulcer Hemorrhage; 6 are open to participants now.
Browse Peptic Ulcer Hemorrhage studies →1 of the 12 studies in Peptic Ulcer Hemorrhage with a site in China is open now. Recruiting first, the newest first:
LanZhou University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 2 Peptic Ulcer Hemorrhage studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 239 is above the median of 162 across 41 interventional studies indexed under Peptic Ulcer Hemorrhage.
Median enrollment 239 across the 7 interventional studies, 845 across the 4 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 4 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Peptic Ulcer Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies in Peptic Ulcer Hemorrhage with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07312370LanZhou UniversityEsomeprazole Plus Sucralfate for Post-ESD Ulcer Healing | 2026-12-20 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Peptic Ulcer Hemorrhage with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic ulcer, with cimetidine i.v. in
A multi-center, randomised, double-blind, parallel-group phase III study to assess high dose esomeprazole Na i.v. treatment (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour administered for 72 hours) for prevention of rebleeding
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Esomeprazole Na · Drug: Esomeprazole Mg
Drug: Cimetidine
Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
Also known as: Nexium
Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
40 mg tablet once daily for 27 days
Also known as: Nexium
Rate of Clinically Significant Rebleeding Within 72 Hours
Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.
Time frame: 72 hours
Rate of Clinically Significant Rebleeding During 7 Days
Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.
Time frame: 7 days
Rate of Clinically Significant Rebleeding During 30 Days
Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.
Time frame: 30 days
Number of Patients With Endoscopic Re-treatment Within 72 Hours
Time frame: 72 hours
Number of Patients With Endoscopic Re-treatment Within 30 Days
Time frame: 30 days
Number of Patients With Surgery Due to Rebleeding Within 72 Hours
Time frame: within 72 hours
Number of Patients With Surgery Due to Rebleeding Within 30 Days
Time frame: within 30 days
Number of Blood Units Transfused Within 72 Hours
Time frame: within 72 hours
Number of Blood Units Transfused Within 30 Days
Time frame: within 30 days
Overall, 239 patients were enrolled from 19 centres in China. The first patient entered the study on 26 February 2013 and the last patient completed the study on 30 December 2014. Of the 239 patients enrolled into the study, 222 (92.9%) patients were randomised to treatment.
| Milestone | Esomeprazole | Cimetidine |
|---|---|---|
| Started | 111 | 111 |
| Completed | 102 | 98 |
| Not completed | 9 | 13 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Not treated | 3 | 4 |
Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.
| participants | Esomeprazole | Cimetidine |
|---|---|---|
| No rebleeding | 107 | 101 |
| Rebleeding | 1 | 6 |
Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.
| participants | Esomeprazole | Cimetidine |
|---|---|---|
| No rebleeding | 105 | 101 |
| Rebleeding | 3 | 6 |
Diagnostic criteria for clinically significant rebleeding based on either A, B or C: A) Endoscopy - initiated by clinical signs of bleeding defined as one of B1 or B2 or B3 and endoscopic verification, ie one of A1 or A2. A1: Blood in stomach (this criteria cannot be used during the first 6 hours after primary endoscopic haemostasis). A2: A verified active bleeding from a peptic ulcer (Forrest Ia, Ib). B) A true clinically based definition, at least two of B1 and/or B2 and/or B3. B1: Vomiting of fresh blood or fresh blood in a gastric tube or haematochezia or melaena after a normal stool. B2: Decrease in Hb \>20g/L (or Hct \>6%) during 24 hours or an increase in Hb \<10g/L (or Hct \<3%) despite ≥2 units of blood has been transfused during 24hours. B3: Unstable circulation systolic blood pressure ≤ 90 mmHg or pulse ≥110/min (after have had a stable circulation). C) Haematemesis. Vomiting significant amounts (\>200 ml) of fresh blood as estimated by the investigator.
| participants | Esomeprazole | Cimetidine |
|---|---|---|
| No rebleeding | 105 | 101 |
| Rebleeding | 3 | 6 |
| participants | Esomeprazole | Cimetidine |
|---|---|---|
| No re-treatment | 108 | 106 |
| Re-treatment | 0 | 1 |
| participants | Esomeprazole | Cimetidine |
|---|---|---|
| No re-treatment | 106 | 106 |
| Re-treatment | 2 | 1 |
| participants | Esomeprazole | Cimetidine |
|---|---|---|
| No surgery | 108 | 107 |
| Surgery | 0 | 0 |
| participants | Esomeprazole | Cimetidine |
|---|---|---|
| No surgery | 108 | 106 |
| Surgery | 0 | 1 |
| blood units | Esomeprazole | Cimetidine |
|---|---|---|
| Number of Blood Units Transfused Within 72 Hours | 14 | 21 |
| blood units | Esomeprazole | Cimetidine |
|---|---|---|
| Number of Blood Units Transfused Within 30 Days | 18 | 21 |
Collected over AEs will be collected from the time of the first administration of IP until the end of study, up to 35 days. SAEs will be collected from signed inform consent until the end of the study, up to 36 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole | — | 5/110 (4.5%) | 22/110 (20%) |
| Cimetidine | — | 5/105 (4.8%) | 20/105 (19%) |
| Event | Esomeprazole | Cimetidine |
|---|---|---|
| Duodenal ulcer haemorrhageGastrointestinal disorders | 2/110 | 2/105 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/110 | 1/105 |
| BronchitisInfections and infestations | 0/110 | 1/105 |
| Persecutory delusionPsychiatric disorders | 0/110 | 1/105 |
| NephrolithiasisRenal and urinary disorders | 0/110 | 1/105 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/110 | 0/105 |
| Blood fibrinogen decreasedInvestigations | 1/110 | 0/105 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/110 | 0/105 |
| Event | Esomeprazole | Cimetidine |
|---|---|---|
| Duodenal ulcer haemorrhageGastrointestinal disorders | 2/110 | 2/105 |
| MelaenaGastrointestinal disorders | 1/110 | 2/105 |
| PyrexiaGeneral disorders | 2/110 | 2/105 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/110 | 0/105 |
| DiarrhoeaGastrointestinal disorders | 2/110 | 1/105 |
| BronchitisInfections and infestations | 0/110 | 1/105 |
| Upper respiratory tract infectionInfections and infestations | 0/110 | 1/105 |
| AnaemiaBlood and lymphatic system disorders | 0/110 | 1/105 |
| Haemorrhagic anaemiaBlood and lymphatic system disorders | 0/110 | 1/105 |
| Persecutory delusionPsychiatric disorders | 0/110 | 1/105 |
Among 222 randomised patients, 215 patients received iv treatment: 108 patients in the esomeprazole treatment group and 107 patients in the cimetidine treatment group.
| Age, Continuous(years) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Age | 42.4 ± 12.79 | 41.8 ± 12.96 | 42.1 ± 12.85 |
| Age, Customized(participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| <=65 years | 104 | 103 | 207 |
| >65 years | 4 | 4 | 8 |
| Sex: Female, Male(Participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Female | 25 | 24 | 49 |
| Male | 83 | 83 | 166 |
| Race/Ethnicity, Customized(participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Asian/Chinese | 108 | 107 | 215 |
| Number of patients with one bleeding ulcer(participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Number | 108 | 107 | 215 |
| Forrest class(participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Ia | 5 | 4 | 9 |
| Ib | 58 | 64 | 122 |
| IIa | 33 | 24 | 57 |
| IIb | 12 | 15 | 27 |
| Bleeding ulcer size(mm) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Mean | 8.2 ± 4.8 | 8.1 ± 3.6 | 8.1 ± 4.3 |
| Ulcer location(participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Stomach | 17 | 8 | 25 |
| Duodenum | 84 | 89 | 173 |
| Stomach and Duodenum | 7 | 10 | 17 |
2 further baseline measures are reported on the registry.
The record gives a start of Feb 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole